Valuation: Forte Biosciences, Inc.

Market Cap 1.88B 1.63B 1.53B 1.39B 2.62B 179B 2.66B 17.98B 7.02B 89.77B 7.05B 6.9B 299B P/E 2026 *
-19.4x
P/E 2027 * -18.9x
Enterprise Value 1.88B 1.63B 1.53B 1.39B 2.62B 179B 2.66B 17.98B 7.02B 89.77B 7.05B 6.9B 299B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+0.10%
1 week+0.04%
Current month+0.34%
1 month+74.21%
3 months+211.68%
6 months+139.36%
Current year+181.85%
1 week 76.76
Extreme 76.76
76.9
1 month 40.73
Extreme 40.73
77.2
Current year 15.51
Extreme 15.51
77.2
1 year 10.11
Extreme 10.11
77.2
3 years 4.11
Extreme 4.11
77.2
5 years 4.11
Extreme 4.11
786.75
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 2017-12-31
Director of Finance/CFO 59 2020-02-29
Chief Operating Officer - 2020-09-30
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 2020-05-31
Director/Board Member 79 2022-03-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Financial Officer

884 0.0043%
7/1/26 Fiscal year

Chief Executive Officer

2,598 0.0127%
5/29/26 Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+0.04%+627.15%+248.93% 1.88B
+2.07%+13.76%+65.44%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.91% 54.93B
-4.50%-4.69%+2.82%+463.22% 28.89B
-0.70%-0.92%+47.44%+6.79% 23.9B
-0.67%+1.02%-18.32%-13.84% 23.3B
-0.59%+7.88%+40.87%-20.56% 18.77B
+0.35%+12.02%+257.19%+466.50% 18.41B
-0.57%-3.06%+20.62%+616.44% 16.1B
+0.46%-3.05%+31.49%+135.18% 12.48B
Average -0.47%+4.24%+111.17%+207.51% 26.87B
Weighted average by Cap. -0.26%+3.95%+55.11%+165.91%

Financials

2026 *2027 *
Net sales - -
Net income -91.11M -78.98M -74.03M -67.5M -127M -8.7B -129M -872M -340M -4.35B -342M -335M -14.52B -107M -93.1M -87.27M -79.57M -150M -10.25B -152M -1.03B -401M -5.13B -403M -394M -17.12B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
26-08-13 $76.86 +0.10% 1,150,557
26-08-12 $76.78 -0.12% 1,924,024
26-08-11 $76.87 +0.07% 1,052,519
26-08-10 $76.82 +0.04% 765,246
26-08-07 $76.79 -0.05% 1,163,855
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
76.86USD
Average target price
73.80USD
Spread / Average Target
-3.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock